HEADLINE: CANCER TREATMENT RISK
ANCHOR LEAD: DOES A COMMON PRACTICE IN PROSTATE CANCER TREATMENT LEAD TO HEART TROUBLE? ELIZABETH TRACEY REPORTS
Reducing testosterone levels in men with prostate cancer is one strategy for helping shrink the tumor and slow down its growth. Yet evidence continues to emerge that depleting testosterone may not be beneficial in the long run. Ballantine Carter, a prostate cancer expert at Johns Hopkins, comments.
CARTER: There’s now increasing interest in the association between removing testosterone from the body and increasing cardiovascular disease, and that’s what this study was all about. And I think it was a cleverly designed study. It tells us that this is a risk, especially in older men, and older men who are thinking about androgen deprivation therapy or who are discussing it with their physician. They should be aware that they really need studies to prove that they don’t have coronary artery disease or cardiovascular disease before they start on androgen deprivation therapy. :29
Assessing heart function prior to starting therapy involves just a few standard tests. I’m Elizabeth Tracey reporting.